Literature DB >> 35108607

Frequent Suboptimal Thermocycler Ramp Rate Usage Negatively Impacts GenoType MTBDRsl VER 2.0 Performance for Second-Line Drug-Resistant Tuberculosis Diagnosis.

Brigitta Derendinger1, Margaretha de Vos1, Samantha Pillay1, Rouxjeane Venter1, John Metcalfe2, Yonas Ghebrekristos3, Stephanie Minnies1, Tania Dolby4, Natalie Beylis4, Robin Warren1, Grant Theron5.   

Abstract

Strengthening second-line drug-resistant tuberculosis (TB) detection is a priority. GenoType MTBDRplus VER 2.0 performance is reduced with non-recommended ramp rate usage (temperature change speed between PCR cycles); however, ramp rate's effect on GenoType MTBDRsl VER 2.0 (MTBDRsl) performance, is unknown. Fifty-two Xpert MTB/RIF Ultra-positive rifampicin-resistant smear-negative sputa and a Mycobacterium tuberculosis dilution series were tested at a manufacturer-recommended (2.2°C/second) or suboptimal (4.0°C/second) ramp rate. M. tuberculosis-complex-DNA positivity, indeterminates, fluoroquinolone- and second-line injectable-resistance accuracy, banding differences, and, separately, inter-reader variability were assessed. Five (39%) of 13 re-surveyed laboratories did not use the manufacturer-recommended ramp rate. On sputum, 2.2°C/second improved indeterminates versus 4.0°C/second (0 of 52 versus 7 of 51; P = 0.006), incorrect drug-class diagnostic calls (0 of 104 versus 6 of 102; P = 0.013), and incorrect banding calls (0 of 1300 versus 54 of 1275; P < 0.001). Similarly, 2.2°C/second improved valid results [(52 of 52 versus 41 of 51; +21% (P = 0.001)] and banding call inter-reader variability [34 of 1300 (3%) versus 52 of 1300 (4%); P = 0.030]. At the suboptimal ramp rate, false-resistance and false-susceptible calls resulted from wild-type band absence rather than mutant band appearance, resulting in misclassification of moxifloxacin resistance level from high-to-low. Suboptimal ramp rate contributes to poor MTBDRsl performance. Laboratories must ensure that the manufacturer-recommended ramp rate is used.
Copyright © 2022 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35108607      PMCID: PMC9127458          DOI: 10.1016/j.jmoldx.2022.01.003

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.341


  9 in total

1.  Averting epidemics of extensively drug-resistant tuberculosis.

Authors:  Sanjay Basu; Gerald H Friedland; Jan Medlock; Jason R Andrews; N Sarita Shah; Neel R Gandhi; Anthony Moll; Prashini Moodley; A Willem Sturm; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-13       Impact factor: 11.205

Review 2.  GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs.

Authors:  Grant Theron; Jonny Peter; Marty Richardson; Rob Warren; Keertan Dheda; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2016-09-08

3.  Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis.

Authors:  David W Dowdy; Grant Theron; Jeffrey A Tornheim; Robin Warren; Emily A Kendall
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

4.  Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis.

Authors:  G L Hobby; A P Holman; M D Iseman; J M Jones
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

5.  Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.

Authors:  E De Vos; L Scott; Y Voss De Lima; R M Warren; W Stevens; C Hayes; P da Silva; A Van Rie
Journal:  Int J Tuberc Lung Dis       Date:  2021-02-01       Impact factor: 2.373

Review 6.  The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Gary Maartens; Kelly E Dooley; Megan Murray; Jennifer Furin; Edward A Nardell; Robin M Warren
Journal:  Lancet Respir Med       Date:  2019-09       Impact factor: 30.700

7.  Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

Authors:  Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Patrick P J Phillips; Kia Bryant; Kelly E Dooley; Melissa Engle; Stefan V Goldberg; Ha T T Phan; James Hakim; John L Johnson; Madeleine Lourens; Neil A Martinson; Grace Muzanyi; Kim Narunsky; Sandy Nerette; Nhung V Nguyen; Thuong H Pham; Samuel Pierre; Anne E Purfield; Wadzanai Samaneka; Radojka M Savic; Ian Sanne; Nigel A Scott; Justin Shenje; Erin Sizemore; Andrew Vernon; Ziyaad Waja; Marc Weiner; Susan Swindells; Richard E Chaisson
Journal:  N Engl J Med       Date:  2021-05-06       Impact factor: 176.079

8.  Cost analysis of rapid diagnostics for drug-resistant tuberculosis.

Authors:  Erik J Groessl; Theodore G Ganiats; Naomi Hillery; Andre Trollip; Roberta L Jackson; Donald G Catanzaro; Timothy C Rodwell; Richard S Garfein; Camilla Rodrigues; Valeriu Crudu; Thomas C Victor; Antonino Catanzaro
Journal:  BMC Infect Dis       Date:  2018-03-02       Impact factor: 3.090

9.  Widespread use of incorrect PCR ramp rate negatively impacts multidrug-resistant tuberculosis diagnosis (MTBDRplus).

Authors:  B Derendinger; M de Vos; R R Nathavitharana; T Dolby; J A Simpson; P D van Helden; R M Warren; G Theron
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.